Year |
Citation |
Score |
2019 |
Blazkova J, Refsland EW, Clarridge KE, Shi V, Justement JS, Huiting ED, Gittens KR, Chen X, Schmidt SD, Liu C, Doria-Rose N, Mascola JR, Heredia A, Moir S, Chun TW. Glycan-dependent HIV-specific neutralizing antibodies bind to cells of uninfected individuals. The Journal of Clinical Investigation. PMID 31589168 DOI: 10.1172/JCI125955 |
0.324 |
|
2018 |
Clarridge KE, Blazkova J, Einkauf K, Petrone M, Refsland EW, Justement JS, Shi V, Huiting ED, Seamon CA, Lee GQ, Yu XG, Moir S, Sneller MC, Lichterfeld M, Chun TW. Effect of analytical treatment interruption and reinitiation of antiretroviral therapy on HIV reservoirs and immunologic parameters in infected individuals. Plos Pathogens. 14: e1006792. PMID 29324842 DOI: 10.1371/journal.ppat.1006792 |
0.357 |
|
2014 |
Refsland EW, Hultquist JF, Luengas EM, Ikeda T, Shaban NM, Law EK, Brown WL, Reilly C, Emerman M, Harris RS. Natural polymorphisms in human APOBEC3H and HIV-1 Vif combine in primary T lymphocytes to affect viral G-to-A mutation levels and infectivity. Plos Genetics. 10: e1004761. PMID 25411794 DOI: 10.1371/Journal.Pgen.1004761 |
0.733 |
|
2013 |
Refsland EW, Harris RS. The APOBEC3 family of retroelement restriction factors. Current Topics in Microbiology and Immunology. 371: 1-27. PMID 23686230 DOI: 10.1007/978-3-642-37765-5_1 |
0.559 |
|
2013 |
Burns MB, Lackey L, Carpenter MA, Rathore A, Land AM, Leonard B, Refsland EW, Kotandeniya D, Tretyakova N, Nikas JB, Yee D, Temiz NA, Donohue DE, McDougle RM, Brown WL, et al. APOBEC3B is an enzymatic source of mutation in breast cancer. Nature. 494: 366-70. PMID 23389445 DOI: 10.1038/Nature11881 |
0.728 |
|
2013 |
Burns MB, Lackey L, Carpenter MA, Rathore A, Land AM, Leonard B, Refsland EW, Kotandeniya D, Tretyakova N, Nikas JB, Yee D, Temiz NA, Donohue DE, McDougle RM, Brown WL, et al. Correction: Corrigendum: APOBEC3B is an enzymatic source of mutation in breast cancer Nature. 502: 580-580. DOI: 10.1038/Nature12667 |
0.715 |
|
2012 |
Refsland EW, Hultquist JF, Harris RS. Endogenous origins of HIV-1 G-to-A hypermutation and restriction in the nonpermissive T cell line CEM2n. Plos Pathogens. 8: e1002800. PMID 22807680 DOI: 10.1371/Journal.Ppat.1002800 |
0.753 |
|
2011 |
Hultquist JF, Lengyel JA, Refsland EW, LaRue RS, Lackey L, Brown WL, Harris RS. Human and rhesus APOBEC3D, APOBEC3F, APOBEC3G, and APOBEC3H demonstrate a conserved capacity to restrict Vif-deficient HIV-1. Journal of Virology. 85: 11220-34. PMID 21835787 DOI: 10.1128/Jvi.05238-11 |
0.664 |
|
2011 |
Burns MB, Lackey L, Land A, Rathore A, Refsland E, Harris R. Abstract LB-193: APOBEC3 catalyzed genomic mutations in breast cancer Cancer Research. 71. DOI: 10.1158/1538-7445.Am2011-Lb-193 |
0.72 |
|
2010 |
Refsland EW, Stenglein MD, Shindo K, Albin JS, Brown WL, Harris RS. Quantitative profiling of the full APOBEC3 mRNA repertoire in lymphocytes and tissues: implications for HIV-1 restriction. Nucleic Acids Research. 38: 4274-84. PMID 20308164 DOI: 10.1093/Nar/Gkq174 |
0.704 |
|
2005 |
Refsland EW, Livingston DM. Interactions among DNA ligase I, the flap endonuclease and proliferating cell nuclear antigen in the expansion and contraction of CAG repeat tracts in yeast. Genetics. 171: 923-34. PMID 16079237 DOI: 10.1534/Genetics.105.043448 |
0.353 |
|
Low-probability matches (unlikely to be authored by this person) |
2019 |
Kuo L, Lawrence D, McDonald D, Refsland E, Bridges S, Smiley S, Tressler RL, Beaubien C, Salzwedel K. Highlights from the Fourth Biennial Strategies for an HIV Cure Meeting, 10–12 October 2018, Bethesda, MD, USA Journal of Virus Eradication. 5: 50-59. DOI: 10.1016/s2055-6640(20)30280-6 |
0.296 |
|
2017 |
Sneller MC, Justement JS, Gittens KR, Petrone ME, Clarridge KE, Proschan MA, Kwan R, Shi V, Blazkova J, Refsland EW, Morris DE, Cohen KW, McElrath MJ, Xu R, Egan MA, et al. A randomized controlled safety/efficacy trial of therapeutic vaccination in HIV-infected individuals who initiated antiretroviral therapy early in infection. Science Translational Medicine. 9. PMID 29212716 DOI: 10.1126/scitranslmed.aan8848 |
0.28 |
|
2023 |
Greenberg AE, Wutoh A, Bowleg L, Robinson B, Magnus M, Segarra L, Simon P, Wutoh A, Blankenship K, Burke M, Okeke NL, Corneli A, Hussen S, Holliday RC, Ciaranello A, ... ... Refsland E, et al. Centers for AIDS Research (CFAR) Diversity, Equity, and Inclusion Pathway Initiative (CDEIPI): Developing Career Pathways for Early-Stage Scholars From Racial and Ethnic Groups Underrepresented in HIV Science and Medicine. Journal of Acquired Immune Deficiency Syndromes (1999). 94: S5-S12. PMID 37707842 DOI: 10.1097/QAI.0000000000003270 |
0.261 |
|
2010 |
de Jong EP, Xie H, Onsongo G, Stone MD, Chen XB, Kooren JA, Refsland EW, Griffin RJ, Ondrey FG, Wu B, Le CT, Rhodus NL, Carlis JV, Griffin TJ. Quantitative proteomics reveals myosin and actin as promising saliva biomarkers for distinguishing pre-malignant and malignant oral lesions. Plos One. 5: e11148. PMID 20567502 DOI: 10.1371/Journal.Pone.0011148 |
0.254 |
|
2019 |
Kuo L, Lawrence D, McDonald D, Refsland E, Bridges S, Smiley S, Tressler RL, Beaubien C, Salzwedel K. Highlights from the Fourth Biennial Strategies for an HIV Cure Meeting, 10-12 October 2018, Bethesda, MD, USA. Journal of Virus Eradication. 5: 50-59. PMID 30800428 |
0.243 |
|
2016 |
Bar KJ, Sneller MC, Harrison LJ, Justement JS, Overton ET, Petrone ME, Salantes DB, Seamon CA, Scheinfeld B, Kwan RW, Learn GH, Proschan MA, Kreider EF, Blazkova J, Bardsley M, ... Refsland EW, et al. Effect of HIV Antibody VRC01 on Viral Rebound after Treatment Interruption. The New England Journal of Medicine. 375: 2037-2050. PMID 27959728 DOI: 10.1056/Nejmoa1608243 |
0.233 |
|
2023 |
Greenberg AE, Wutoh AK, Bowleg L, Magnus M, Robinson B, Segarra L, Refsland E. Supplemental Issue of the Journal of the Acquired Immune Deficiency Syndromes (JAIDS): The Centers for AIDS Research (CFAR) Diversity, Equity, and Inclusion Pathway Initiative (CDEIPI). Journal of Acquired Immune Deficiency Syndromes (1999). 94: S1-S4. PMID 37707841 DOI: 10.1097/QAI.0000000000003258 |
0.083 |
|
Hide low-probability matches. |